SCHEDULE 13G: Foresite Capital and James Tananbaum Disclose Significant Passive Stake in Maze Therapeutics

Foresite Capital entities and James Tananbaum have filed a Schedule 13G, revealing a combined beneficial ownership of 5.6% of Maze Therapeutics, Inc.'s common stock as of January 31, 2025.

Summary

• Foresite Capital Fund IV, L.P. (FCF IV) beneficially owns 2,111,917 shares, representing 4.8% of Maze Therapeutics, Inc. common stock.
• Foresite Capital Management IV, LLC (FCM IV), as the general partner of FCF IV, is deemed to have sole voting and dispositive power over these 2,111,917 shares.
• Foresite Capital Fund V, L.P. (FCF V) beneficially owns 345,191 shares, representing 0.8% of Maze Therapeutics, Inc. common stock.
• Foresite Capital Management V, LLC (FCM V), as the general partner of FCF V, is deemed to have sole voting and dispositive power over these 345,191 shares.
• James Tananbaum, as the managing member of both FCM IV and FCM V, is deemed to have sole voting and dispositive power over an aggregate of 2,457,108 shares, which constitutes 5.6% of the Issuer's outstanding common stock.
• The percentage ownership is calculated based on 43,776,978 shares of Maze Therapeutics, Inc. common stock outstanding as of January 31, 2025.
• The filing indicates a passive investment purpose, with no intent to change or influence control of the Issuer.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it indicates a significant, passive investment by a reputable venture capital firm and its managing member, suggesting confidence in the company without implying any immediate operational changes or challenges.

Positives

• A significant institutional investor, Foresite Capital, and its managing member, James Tananbaum, have disclosed a substantial passive stake in Maze Therapeutics, indicating confidence in the company.
• James Tananbaum's aggregate beneficial ownership of 5.6% crosses the 5% threshold, making him a notable shareholder.

Future Outlook

The Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding Maze Therapeutics, Inc.'s future operations or financial performance.

Management Comments

• "The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

This filing indicates continued investment interest from venture capital firms like Foresite Capital in the biotechnology sector, specifically in companies like Maze Therapeutics. Such passive stakes by institutional investors are common and can signal long-term confidence in a company's potential within its industry.

Comparison to Industry Standards

• As a Schedule 13G filing, this document primarily reports beneficial ownership and does not provide financial or operational results for direct comparison to industry standards. However, the disclosed 5.6% stake by James Tananbaum, a prominent figure associated with Foresite Capital, aligns with typical institutional investment strategies in early to mid-stage biotechnology companies, where significant stakes are taken to support growth without seeking active control.

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by a notable institutional investor may be viewed positively, potentially increasing investor confidence.

Next Steps

• The reporting persons will continue to monitor their investment in Maze Therapeutics, Inc.
• Future Schedule 13G or 13D amendments will be filed if there are material changes to their beneficial ownership or investment intent.

Key Dates

Recommendation

Keywords

Maze Therapeutics, Foresite Capital, James Tananbaum, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Healthcare Investment